ONO-7475 + ONO-4538 + Nab-paclitaxel + Gemcitabine
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Cancer
Conditions
Metastatic Pancreatic Cancer
Trial Timeline
Dec 6, 2023 → Mar 31, 2028
NCT ID
NCT06532331About ONO-7475 + ONO-4538 + Nab-paclitaxel + Gemcitabine
ONO-7475 + ONO-4538 + Nab-paclitaxel + Gemcitabine is a phase 1 stage product being developed by Ono Pharmaceutical for Metastatic Pancreatic Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06532331. Target conditions include Metastatic Pancreatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06532331 | Phase 1 | Active |
Competing Products
20 competing products in Metastatic Pancreatic Cancer